Provention Bio, Inc. PRVB Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Sep'17	Jun'17	Dec'16
Operating expenses:
Research and development
35,427	36,359	32,861	29,677	28,288	22,649	18,571	18,162	0	0	0	-
General and administrative
10,551	8,013	6,829	5,452	4,749	4,165	3,417	2,401	0	0	0	0
Total operating expenses
45,978	44,372	39,690	35,129	33,037	26,814	21,988	20,563	0	0	0	0
Loss from operations
-45,978	-44,372	-39,690	-35,129	-33,037	-26,814	-21,988	-20,563	0	0	0	0
Interest income
1,083	1,087	981	822	0	-	0	0	-	-	-	-
Interest income
-	-	-	-	-	-	-	-	0	0	0	-
Change in fair value of warrant liability
-	-	-	-	-	520	557	426	0	0	0	-
Loss before income tax benefit
-44,895	-43,285	-38,616	-34,239	-32,574	-26,665	0	0	0	-	-	0
Net loss
0	-	-	-	0	-	-	-	-	-	-	-
Accretion on Series A Convertible Redeemable Preferred Stock
-	-	-	-	-	276	403	468	0	0	0	-
Net loss attributable to common stockholders
-	-	-38,429	-34,077	-	-26,754	-22,559	-21,275	0	0	0	0
Net loss per common share, basic and diluted
-0.26	-0.21	-0.24	-0.32	-0.29	0.55	-0.17	-1.05	-0.52	-0.15	-0.44	-0.02
Weighted average common shares outstanding, basic and diluted
47	85,075	40,512	37,363	37	37,764	32,000	10,000	10,000	10,000	9,473	7,636
Other income (expense), net
-	-	-	-	-	-	-	-	-	0	0	-
Net Loss
-44,895	-43,285	-38,429	-34,052	-32,387	-26,478	-22,156	-20,807	0	0	0	0
Other comprehensive income:
Unrealized gain on marketable securities
0	-	-	-	-	-	-	-	-	-	-	-
Total comprehensive loss
0	-	-	-	0	-	-	-	-	-	-	-